FOR IMMEDIATE RELEASE
July 17, 2025
WASHINGTON, DC — LLA Technologies has been officially selected to present its flagship innovation, Recordis™, at the upcoming Healthy America 2025 conference, taking place in Washington, DC from July 23–25, 2025. The event— inspired by the Make America Healthy Again and Patient First movements—brings together national health leaders, policymakers, and innovators focused on transforming healthcare through prevention, accessibility, and technology.
Recordis is a portable, non-invasive cardiac monitoring device that completes a full cardiac-function analysis in just one minute. Using seismocardiography (SCG)—a method that measures the mechanical activity of the heart through subtle chest vibrations—Recordis enables rapid, accessible, and data-rich cardiac screening without the need for specialized facilities.
Chosen as one of only 15 companies featured at Healthy America 2025, LLA’s selection reflects both the disruptive potential of Recordis and its alignment with the conference’s vision for scalable, frontline-ready healthcare innovation.
“Recordis has the potential to transform how we detect and manage cardiovascular risk for people across all walks of life—regardless of age, geography, or access to care,” said Dave Loban, CEO of LLA Technologies. “Whether it’s used in a busy urban clinic or a remote frontline setting, the value is the same: it’s fast, non-invasive, cost-effective, and scalable. Being selected to present at Healthy America 2025 is an incredible opportunity to share what we’ve built with health leaders and to open the door for meaningful partnerships.”
LLA’s team includes military veterans, former UN and NGO emergency responders, PhD cardiac scientists, and kinesiologists—professionals who have spent decades working in complex healthcare environments worldwide. That background directly shaped Recordis: a device designed not just for hospitals, but for the real-world challenges of preventive care, occupational health, mental-health resilience, and underserved populations.
The company has already deployed Recordis in pilot projects with public-safety and clinical partners, including remote testing environments and frontline personnel. The technology is now being introduced to primary-care clinics and community-based providers.
After more than 17 years of R&D, Healthy America 2025 marks a defining moment for LLA Technologies as it transitions to commercial deployment. The company is actively engaging with strategic investors and health-system partners to scale access to Recordis across North America and globally.
About LLA Technologies
Founded in 2007, LLA Technologies Inc. is an ISO 13485 and MDSAP certified Canadian medical device company dedicated to advancing cardiac care through innovation. The company’s flagship product, Recordis™, is a Health Canada Class II approved device that captures comprehensive cardiac data through seismocardiography (SCG) in just 60 seconds. With over 65,000 tests completed and 11 published papers, Recordis enables clinical-grade cardiac screening wherever care happens—from mental health and primary care to sports medicine and remote healthcare settings. The company is currently pursuing FDA 510(k) clearance. Learn more at recordis.com
###
LLA Technologies Inc.
For more information:
[email protected]
recordis.com
LinkedIn